Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Journal
Targeted oncology
Date Issued
2022-11-05
Author(s)
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Chen, Jeremy J W
Chang, Gee-Chen
Abstract
The article The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non- Small Cell Lung Cancer in Taiwan, written by Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen and Gee-Chen Chang, was originally published electronically in SpringerLink on 23 April 2022 without open access. After publication in volume 17, issue 3, pages 295–306 with the author(s)’ decision to opt for Open Choice the copyright of the article changed on 1 November 2022 to © The Author(s) 2022 and article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. The original article has been corrected.
SDGs
Publisher
SPRINGER
Type
corrigendum